Clinical Scorecard: Comprehensive Care Strategies for Managing Wounds Related to Xylazine Use
At a Glance
Category
Detail
Condition
Xylazine-associated wounds (XAWs), chronic wounds often with full-thickness necrosis and superinfection
Key Mechanisms
Xylazine as an alpha-2 adrenergic agonist adulterant in illicit fentanyl causing tissue necrosis and chronic wounds, sometimes distant from injection sites
Target Population
Persons who use drugs (PWUD), especially those exposed to illicitly manufactured fentanyl adulterated with xylazine
Care Setting
Multidisciplinary outpatient and inpatient settings including wound care clinics, addiction medicine, infectious diseases, surgery, and emergency departments
Key Highlights
XAWs often present as large, chronic wounds with full-thickness necrosis, frequently on extremities and extensor surfaces.
Diagnosis is clinical in high-prevalence areas; urine xylazine testing may aid diagnosis where available.
Multidisciplinary care involving addiction medicine, wound care, infectious diseases, surgery, and peer navigation is essential.
Guideline-Based Recommendations
Diagnosis
Diagnose XAWs clinically in areas with high xylazine prevalence in illicit fentanyl.
Consider differential diagnoses including typical skin and soft tissue infections and injuries.
Use urine xylazine testing with mass spectrometry or rapid test strips where available, noting limitations.
Management
Avoid aggressive debridement of wounds due to tissue necrosis.
Administer empirical antibiotics targeting MRSA and group A Streptococcus: oral trimethoprim-sulfamethoxazole for MRSA and oral β-lactams for GAS.
Use intravenous daptomycin to reduce discomfort and challenges of vancomycin monitoring.
Develop contingency antibiotic plans including linezolid, tedizolid, or dalbavancin for patient-directed hospital discharge.
Provide substance use disorder treatment alongside wound care.
Monitoring & Follow-up
Monitor wound progression and signs of superinfection regularly.
Coordinate longitudinal multidisciplinary follow-up including addiction medicine and infectious diseases.
Adjust antibiotic therapy based on clinical response and microbiological data.
Risks
Risk of limb loss due to severe tissue destruction and infection.
Potential for superinfection with MRSA and group A Streptococcus.
Challenges related to patient adherence and stigma impacting care engagement.
Patient & Prescribing Data
Persons who use drugs with xylazine-associated wounds, often with opioid use disorder
Empirical antibiotic regimens should cover MRSA and GAS; intravenous daptomycin preferred over vancomycin for ease of monitoring; contingency oral antibiotics facilitate discharge planning.
Clinical Best Practices
Implement a multidisciplinary care team including peer navigators, addiction specialists, wound care, infectious diseases, and surgical services.
Proactively inquire about XAWs in PWUD due to stigma and wound heterogeneity.
Avoid aggressive wound debridement to prevent further tissue damage.
Use empirical antibiotics targeting common pathogens with consideration for patient discharge planning.
Incorporate substance use disorder treatment as a core component of wound management.
by Wei-Teng Yang, Jessica A Meisner, Christina Maguire, Kelly E Dyer, Rachel McFadden, Ashish P Thakrar, Drew T Dickinson, Deanna Berg, Ave Preston, Michael Z David, Jeanmarie Perrone, Naasha Talati, Kathleen O Degnan
